FDA gets new power to yank fake supplements off shelves
H.R. 7407 — Prohibiting Tianeptine and Other Dangerous Products Act of 2026 · Filed by Frank Pallone (D-NJ) · Introduced Feb 5, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill amends federal food and drug law to prohibit the sale and importation of dietary supplements that either (1) are marketed as dietary supplements but don't legally qualify as such, or (2) were made with help from someone barred from the industry. It gives FDA authority to seize and exclude such products at the border. The bill targets products like tianeptine—a substance sold as a supplement but with drug-like effects—that exploit regulatory gaps.
Why we flagged it
The bill's operative mechanism is straightforward: it expands FDA's authority to identify and remove dietary supplements that are mislabeled or made by disqualified parties. This is a public-health enforcement tool, not a subsidy, carve-out, or deregulation.
What the text implies
- The bill's effectiveness depends on FDA's capacity to test and verify whether products meet the statutory definition of 'dietary supplement'—a resource-intensive task that may require appropriations not specified in the text.
- Products currently on shelves marketed as supplements but failing the legal definition may face sudden removal, creating supply-chain disruption for retailers and potential consumer confusion about what was previously available.
The full analysis lists 3 implications of this text.
Who stands to gain
Legitimate dietary supplement manufacturers (competitive advantage over non-compliant competitors); FDA (expanded enforcement authority and potential budget justification)